Author:
Sato Sho,Kunisaki Chikara,Tanaka Yusaku,Sato Kei,Miyamoto Hiroshi,Yukawa Norio,Kosaka Takashi,Akiyama Hirotoshi,Endo Itaru,Misumi Toshihiro
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Ferlay JEM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer 2018.
https://gco.iarc.fr/today
.
2. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687–97.
3. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9(3):215–21.
4. Sawaki A, Ohashi Y, Omuro Y, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer. 2012; 15(3):313–22.
5. Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015; 26(1):141–8.
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献